Literature DB >> 34912594

Sporadic Noradrenergic Adrenal Pheochromocytoma in an Adolescent Patient.

Sasi K Penukonda1, Craig B Chu2.   

Abstract

Pheochromocytoma and paraganglioma are neuroendocrine tumors that occur less commonly among children compared to adults. The excess catecholamines secreted by the tumor cells result in hypertension, tachycardia, excess sweating, and headache. Other symptoms include abdominal pain or distension caused by the adrenal mass. Here, we report a case of pheochromocytoma arising from the left adrenal medulla in a 14-year-old boy, which was exclusively secreting norepinephrine, as suggested by elevated plasma and 24-hour urinary norepinephrine and its metabolite normetanephrine. The epinephrine and its metabolite metanephrine were within normal limits. He presented with abdominal pain, recurrent vomiting, and headache and was noted to have elevated blood pressure. He underwent adrenalectomy after controlling his blood pressure with an alpha-blocker Prazosin. His blood pressure remained stable after surgery, and his plasma-free metanephrines returned to normal limits. He tested negative for hereditary paraganglioma-pheochromocytoma gene panel.
Copyright © 2021, Penukonda et al.

Entities:  

Keywords:  adrenal; catecholamines; metanephrines; paraganglioma; pheochromocytoma

Year:  2021        PMID: 34912594      PMCID: PMC8664276          DOI: 10.7759/cureus.19443

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Pheochromocytoma and paraganglioma are rare neuroendocrine tumors arising from the catecholamine-producing chromaffin cells of the adrenal medulla or paraganglia with an estimated incidence of 0.11 per million children [1]. Hypertension is the most consistent manifestation of these tumors, and it is more likely seen in children with or without paroxysmal crisis superimposed [2]. The excess catecholamines produced are mostly metabolized to metanephrines within the tumor cells by membrane-bound catecholamine O-methyltransferase [3]. Hence, the Endocrine Society guidelines recommend the measurement of plasma-free metanephrines or urinary fractionated metanephrines to diagnose pheochromocytoma and paraganglioma [4]. The catecholamine phenotype varies in pheochromocytoma and paraganglioma, with most paragangliomas presenting with lower epinephrine and metanephrine plasma concentrations compared to pheochromocytoma [5]. Here, we report a case of pheochromocytoma in a 14-year-old adolescent male patient with excess norepinephrine and normetanephrine but normal epinephrine and metanephrine levels.

Case presentation

A 14-year-old adolescent male patient presented with incidentally discovered left adrenal mass measuring 6 × 6 × 7.4 cm on a computed tomography (CT) scan (Figure 1) while being investigated for vague left upper abdominal pain and recurrent vomiting. On further questioning, he reported frequent headaches. There was no history of palpitations or excess sweating. His blood pressure was elevated around 140/78 mmHg, and his heart rate was 103 beats per minute.
Figure 1

Coronal MPR CT image with contrast demonstrating heterogeneously enhancing left adrenal mass (black arrow).

MPR: multiplanar reformation; CT: computed tomography

Coronal MPR CT image with contrast demonstrating heterogeneously enhancing left adrenal mass (black arrow).

MPR: multiplanar reformation; CT: computed tomography Further investigations revealed elevated plasma-free normetanephrine and 24-hour urine normetanephrine and norepinephrine. Plasma-free metanephrine and 24-hour urine metanephrine and epinephrine were within normal limits (Table 1).
Table 1

Laboratory findings at initial presentation.

Plasma-free metanephrines 24-hour urinary fractionated metanephrines 24-hour urinary fractionated catecholamines
Free normetanephrine Free metanephrine Normetanephrine Metanephrine Norepinephrine Epinephrine
30 nmol/L <0.2 nmol/L 8,887 µg/24 hour 92 µg/24 hour 574 µg/24 hour 1.9 µg/24 hour
Reference range
<0.9 nmol/L <0.5 nmol/L 91–456 µg/24 hour 69–221 µg/24 hour 15–80 µg/24 hour 0.5–20 µg/24 hour
Iodine-123 meta-iodobenzylguanidine scan revealed intense uptake in the region of mass in the left adrenal gland. No other abnormal areas of uptake were noted throughout the chest, abdomen, pelvis, extremities, head, and neck (Figure 2).
Figure 2

MIBG scan images showing intense uptake of iodine-123 in the region of the left adrenal mass (yellow arrow).

MIBG: meta-iodobenzylguanidine

MIBG scan images showing intense uptake of iodine-123 in the region of the left adrenal mass (yellow arrow).

MIBG: meta-iodobenzylguanidine He was treated with an alpha-blocker prazosin for two weeks prior to adrenalectomy to control his blood pressure. He was also advised a high-salt diet and increased fluid intake to expand blood volume and prevent hypotension after removal of the tumor. The patient underwent robot-assisted left adrenalectomy, and his postoperative period was uneventful. Prazosin was discontinued as his blood pressure remained stable after surgery. Biopsy confirmed the diagnosis of pheochromocytoma. His plasma-free metanephrine levels two weeks after surgery were normal (Table 2).
Table 2

Plasma-free metanephrine levels before and after surgery.

Plasma-free metanephrines Before surgery Two weeks after surgery Reference range
Free normetanephrine 30 nmol/L 0.59 nmol/L <0.9 nmol/L
Free metanephrine <0.2 nmol/L <0.2 nmol/L <0.5 nmol/L
He tested negative for hereditary paraganglioma-pheochromocytoma gene panel, including Von Hippel-Lindau (VHL), succinate dehydrogenase complex subunit B (SDHB), succinate dehydrogenase complex subunit D (SDHD), and RET genes.

Discussion

Pheochromocytomas and paragangliomas are heterogenous tumors with diverse phenotypes. Paragangliomas predominantly or exclusively secrete norepinephrine, whereas epinephrine secretion is usually confined to pheochromocytomas arising from the adrenal medulla [6]. The excess production of epinephrine limited to tumors arising from the adrenal medulla is thought to be due to the proximity of these tumors to adrenal cortical steroids, which induce the production of phenylethanolamine-N-methyltransferase (PNMT), the enzyme that converts norepinephrine to epinephrine [7]. However, it was later demonstrated that neither in vivo (direct contact between pheochromocytes and cortical cells) nor in vitro (pheochromocytes treated with dexamethasone) is sufficient to ensure PNMT transcription [5]. Approximately one-half of adrenal tumors produce nearly exclusively norepinephrine, and the other half produce a variable mixture of epinephrine and norepinephrine [8,9]. Our patient had adrenal pheochromocytoma exclusively producing norepinephrine. One study revealed that noradrenergic tumors usually present with sustained hypertension, as seen in our patient, and the tumors producing high levels of epinephrine cause paroxysmal hypertension [10]. More than 50% of patients aged less than 20 who present with pheochromocytoma/paraganglioma were found to have identifiable germline mutations, and the most common genes involved were VHL, RET, SDHD, and SDHB [11]. The catecholamine phenotype in hereditary pheochromocytomas can vary with underlying gene mutation, with those from Von Hippel-Lindau syndrome (VHL gene mutation) producing predominantly norepinephrine, and the tumors from multiple endocrine neoplasia type 2 (RET gene mutation) producing a mixture of epinephrine and norepinephrine [12]. Our patient tested negative for all common genetic mutations associated with pheochromocytoma, suggesting sporadic type. Surgical excision is the treatment of choice. Hormonally functional pheochromocytomas need treatment with alpha-blockers such as phenoxybenzamine or prazosin to prevent perioperative cardiovascular complications. Another option is the administration of calcium channel blockers. Beta-blockers can be added to control tachycardia after administration of alpha-blockers. Other supportive care includes a high-sodium diet and increased fluid intake to reverse catecholamine-induced blood volume contraction preoperatively, and thereby prevent severe hypotension after tumor removal [4,13]. Recent advances in laparoscopic surgery have increased the feasibility of laparoscopic adrenalectomy in pheochromocytoma [14,15]. Open surgery is recommended for tumors greater than 6 cm as it allows complete removal of the tumor and minimizes systemic catecholamine release [4]. Adrenal “cortical sparing” procedures have been advocated for patients with bilateral tumors to avoid the need for long-term steroid replacement and the risk of Addisonian crisis [15]. Our patient underwent robot-assisted adrenalectomy with one of the abdominal incisions widened to remove the intact adrenal mass.

Conclusions

Pheochromocytoma and paraganglioma are relatively rare in the pediatric population. Children presenting with adrenal mass or hypertension should be investigated for pheochromocytoma. Measurement of catecholamine metabolites such as normetanephrine and metanephrine in plasma and 24-hour urine helps accurately diagnose these tumors. Children diagnosed with pheochromocytoma/paraganglioma need further evaluation to rule out germline mutations associated with these tumors.
  14 in total

1.  Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma.

Authors:  M Gagner; A Lacroix; E Bolté
Journal:  N Engl J Med       Date:  1992-10-01       Impact factor: 91.245

2.  Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines.

Authors:  Graeme Eisenhofer; Jacques W M Lenders; David S Goldstein; Massimo Mannelli; Gyorgy Csako; McClellan M Walther; Frederieke M Brouwers; Karel Pacak
Journal:  Clin Chem       Date:  2005-02-17       Impact factor: 8.327

3.  Germ-line mutations in nonsyndromic pheochromocytoma.

Authors:  Hartmut P H Neumann; Birke Bausch; Sarah R McWhinney; Bernhard U Bender; Oliver Gimm; Gerlind Franke; Joerg Schipper; Joachim Klisch; Carsten Altehoefer; Klaus Zerres; Andrzej Januszewicz; Charis Eng; Wendy M Smith; Robin Munk; Tanja Manz; Sven Glaesker; Thomas W Apel; Markus Treier; Martin Reineke; Martin K Walz; Cuong Hoang-Vu; Michael Brauckhoff; Andreas Klein-Franke; Peter Klose; Heinrich Schmidt; Margarete Maier-Woelfle; Mariola Peçzkowska; Cesary Szmigielski; Charis Eng
Journal:  N Engl J Med       Date:  2002-05-09       Impact factor: 91.245

4.  Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.

Authors:  G Eisenhofer; M M Walther; T T Huynh; S T Li; S R Bornstein; A Vortmeyer; M Mannelli; D S Goldstein; W M Linehan; J W Lenders; K Pacak
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

Review 5.  Perioperative Management of Pheochromocytoma.

Authors:  Julian Naranjo; Sarah Dodd; Yvette N Martin
Journal:  J Cardiothorac Vasc Anesth       Date:  2017-02-04       Impact factor: 2.628

6.  Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors.

Authors:  G Eisenhofer; H Keiser; P Friberg; E Mezey; T T Huynh; B Hiremagalur; T Ellingson; S Duddempudi; A Eijsbouts; J W Lenders
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

7.  Recent advances in the diagnosis and treatment of pheochromocytoma in children.

Authors:  Andrew D Ludwig; Daniel I Feig; Mary L Brandt; M John Hicks; Megan E Fitch; Darrell L Cass
Journal:  Am J Surg       Date:  2007-12       Impact factor: 2.565

8.  The value of plasma markers for the clinical behaviour of phaeochromocytomas.

Authors:  E van der Harst; W W de Herder; R R de Krijger; H A Bruining; H J Bonjer; S W J Lamberts; A H van den Meiracker; T H Stijnen; F Boomsma
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

9.  The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma.

Authors:  Y Ito; Y Fujimoto; T Obara
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?

Authors:  Eric Grouzmann; Oliver Tschopp; Frédéric Triponez; Maurice Matter; Stefan Bilz; Michael Brändle; Tilman Drechser; Sarah Sigrist; Henryk Zulewski; Christoph Henzen; Stefan Fischli; Karim Abid
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.